Dermatology Times, August 2019 (Vol. 39, No. 8)

For many dermatologists, successfully treating patients means taking a more patient-centered approach to care. This table includes 11 tips from Dr. Neil Prose, Duke University Medical Center.

The August issue of Dermatology Times includes a supplement edition that focuses on a patient-centered approach in psoriasis management, including an article on the importance of longer consults in the doctor's office and recommendations for individualized therapy. Read more here.  

The Food and Drug Administration is in the process of evaluating scientific data on the safety of probiotics and postbiotics in cosmetics, said Linda Katz, M.D., director of the Office of Cosmetics and Color for the FDA.

For many dermatologists, successfully treating patients means taking a more patient-centered approach to care. This table includes 11 tips from Dr. Neil Prose, Duke University Medical Center.

A Johns Hopkins study finds that physicians who use stigmatizing language in their patients' medical records, may actually be hurting the care those patients get for years to come.

In June, the European Commission approved tofacitinib citrate (Xeljanz/Pfizer) 5 mg twice daily in combination with methotrexate for adults with psoriatic arthritis. Learn about the parameters here.

While patient-centered medicine works well for patients, what does it mean for the practice?

The new AAD cSCC treatment guidelines highlight alternative therapeutic or preventive treatment options.

Here's a look at new botulinum toxin treatments on the horizon.

In June, Dermira Inc. announced the FDA approval of Qbrexza (glycopyrronium) for primary axillary hyperhidrosis ― excessive underarm sweating.

The intensity and duration of the inflammatory reaction in acne causes dermal damage and alteration of the sebaceous gland structure leading to atrophic scar formation, but not all patients are affected equally.

This is the first time an IL-23 blocking drug has been shown to improve signs and symptoms of psoriatic arthritis.

Oral propranolol may be safe for infants with uncomplicated hemangiomas, but for those with underlying health conditions, it may not always be the treatment of choice.